We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.64 | -4.96% | 12.26 | 12.26 | 12.27 | 135,193 | 12:23:56 |
Conference call details are as follows:
Date: | Monday, February 27, 2017 | |
Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
Passcode: | 61206704 | |
Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
Passcode: | 61206704 | |
Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations ir@novavax.com 240-268-2000 Westwicke Partners John Woolford john.woolford@westwicke.com 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. david.schull@russopartnersllc.com 212-845-4271
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions